LPLuc Puis

Luc Puis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luc Puis has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The never-ending process of adaptation

    by Luc Puis

    AmSECT’s Journal of ExtraCorporeal Technology is the premier global source of the most current research and information related to extracorporeal technology.

  • Open Access

    Haematic antegrade repriming to enhance recovery after cardiac surgery from the perfusionist side

    by Juan Blanco-Morillo, Diego Salmerón Martínez, Jose M. Arribas-Leal, Piero Farina, Luc Puis, Angel J. Sornichero-Caballero, Sergio J. Cánovas-Lόpez

    Background: New era of cardiac surgery aims to provide an enhanced postoperative recovery through the implementation of every step of the process. Thus, perfusion strategy should adopt evidence-based measures to reduce the impact of cardiopulmonary bypass (CPB). Hematic Antegrade Repriming (HAR) provides a standardized procedure combining several measures to reduce haemodilutional priming to 300 mL. Once the safety of the procedure in terms of embolic release has been proven, the evaluation of its beneficial effects in terms of transfusion and ICU stay should be assessed to determine if could be considered for inclusion in Enhanced Recovery After Cardiac Surgery (ERACS) programs.Methods: Two retrospective and non-randomized cohorts of high-risk patients, with similar characteristics, were assessed with a propensity score matching model. The treatment group (HG) (n = 225) received the HAR. A historical cohort, exposed to conventional priming with 1350 mL of crystalloid confirmed the control group (CG) (n = 210).Results: Exposure to any transfusion was lower in treated (66.75% vs. 6.88%,p < 0.01). Prolonged mechanical ventilation (>10 h) (26.51% vs. 12.62%;p < 0.01) and extended ICU stay (>2 d) (47.47% vs. 31.19%;p < 0.01) were fewer for treated. HAR did not increase early morbidity and mortality. Related savings varied from 581 to 2741.94 $/patient, depending on if direct or global expenses were considered.Discussion: By reducing the gaseous and crystalloid emboli during CPB initiation, HAR seems to have a beneficial impact on recovery and reduces the overall transfusion until discharge, leading to significant cost savings per process. Due to the preliminary and retrospective nature of the research and its limitations, our findings should be validated by future prospective and randomized studies.


  • Open Access

    Hematic Antegrade Repriming Reduces Emboli on Cardiopulmonary Bypass: A Randomized Controlled Trial

    by Juan Blanco-Morillo, Diego Salmerón Martínez, Daniel Vicente Morillo-Cuadrado, Jose María Arribas-Leal, Luc Puis, Alicia Verdú-Verdú, Mercedes Martínez-Molina, Encarnación Tormos-Ruiz, Angel Sornichero-Caballero, Pablo Ramírez-Romero, et al.

    Particulate and gaseous microemboli (GME) are side effects of cardiac surgery that interfere with postoperative recovery by causing endothelial dysfunction and vascular blockages. GME sources during surgery are multiple, and cardiopulmonary bypass (CPB) is contributory to this embolic load. Hematic antegrade repriming (HAR) is a novel procedure that combines the benefits of repriming techniques with additional measures, by following a standardized procedure to provide a reproducible hemodilution of 300 ml. To clarify the safety of HAR in terms of embolic load delivery, a prospective and controlled study was conducted, by applying Doppler probes to the extracorporeal circuit, to determine the number and volume of GME released during CPB. A sample of 115 patients (n = 115) was considered for assessment. Both groups were managed under strict normothermia, and similar clinical conditions and protocols, receiving the same open and minimized circuit. Significant differences in GME volume delivery (control group [CG] = 0.28 ml vs. HAR = 0.08 ml; p = 0.004) and high embolic volume exposure (>1 ml) were found between the groups (CG = 30.36% vs. HAR = 4.26%; p = 0.001). The application of HAR did not represent an additional embolic risk and provided a four-fold reduction in the embolic volume delivered to the patient (coefficient, 0.24; 95% CI, 0.08–0.72; p = 0.01), which appears to enhance GME clearance of the oxygenator before CPB initiation.


  • Open Access

    2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery

    by Luc Puis, Milan Milojevic, Christa Boer, Filip M J J De Somer, Tomas Gudbjartsson, Jenny van Den Goor, Timothy J Jones, Vladimir Lomivorotov, Frank Merkle, Marco Ranucci, et al.

    TABLE OF CONTENTS


  • 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery

    by Alexander Wahba, Milan Milojevic, Christa Boer, Filip M J J De Somer, Tomas Gudbjartsson, Jenny van Den Goor, Timothy J Jones, Vladimir Lomivorotov, Frank Merkle, Marco Ranucci, et al.


  • Case report: plasma leakage in a polymethylpentene oxygenator during extracorporeal life support

    by L Puis, L Ampe, R Hertleer

    Plasma leakage is a phenomenon which has almost completely disappeared since the introduction of plasma-tight polymethylpentene (PMP) fibers in oxygenators used for extracorporeal life support (ECLS). We describe here a case of ECLS which was affected by the rapid occurrence of plasma leakage in oxygenators with polymethylpentene fibers. To our knowledge, this is the first report of the phenomenon since the introduction of this new generation of oxygenators.